THE ROLE OF THE HEAT SHOCK PROTEIN 70 IN THE PATHOGENESIS OF CARDIOVASCULAR PATHOLOGY

The problem of studying cardiovascular diseases (CVD) for a long time remains extremely important, and, therefore, there are many works that offer new ways to diagnose and treat this group of diseases. Great opportunities are provided by the study of molecular interactions for a more accurate understanding of the pathogenesis of cardiovascular pathology. Many studies have recently been devoted to finding potential markers of CVD risk with the aim of more accurate and early diagnosis. In this review we analyze the latest literature data dedicated to the role of heat shock protein 70 (HSP70) in cardiovascular pathology. HSP70 take part in such processes as arterial hypertension, coronary heart disease, and atherosclerosis. In atherogenesis, serum heat shock proteins 70 play a major role. It has been proven that in patients with a high concentration of heat shock protein molecules circulating in the blood, increased values of the carotid intima-media complex were observed. The important role of antibodies to circulating HSP70 is noted. Found an association of high levels of these antibodies with atherosclerosis in patients with arterial hypertension in history, with myocardial infarction. Low levels of anti-HSP70 antibodies are observed in patients with acute coronary syndrome. This proves the complexity of the mechanism and the dual role of antibodies against serum heat shock proteins 70. Thus, antibodies against heat shock proteins 70 can be assessed as a protective marker, and as a predictor, which requires further study, and the HSP70 molecules themselves can somehow to participate in the development of cardiovascular pathologies. Much attention is paid to the role of the inflammatory process and the mechanisms of innate immunity in CVD. As it is currently believed that Danger-associated molecular patterns (DAMPs) are involved in the pathogenesis of these pathologies in the context of a “hazard/damage” model. According to this model, the triggering factor is stress, leading to the release of DAMPs and their binding to innate immunity receptors - Toll-like receptors (TLRs). Activation of TLRs triggers the signaling cascade in the cell leading to the synthesis of pro-inflammatory cytokines. This contributes to the development of inflammation, which can provoke the emergence of new pathological processes in the body and worsen the course of existing diseases. The identification of new potential markers and knowledge of the molecular mechanisms of the pathogenesis of CVD can play an important role in the development of a new individual approach to the prevention of cardiovascular diseases.

1. Искаков Е.Б. Эпидемиология сердечно-сосудистых заболеваний // Медицина и экология, 2017. № 2. С. 19-28. [Iskakov E.B. Epidemiology of cardiovascular diseases. Meditsina i ekologiya = Medicine and Ecology, 2017, no. 2, pp. 19-28. (In Russ.)]

2. Ковальчук Л.В., Ганковская Л.В., Мешкова Р.Я. Клиническая иммунология и аллергология с основами общей иммунологии. М.: ГЭОТАР-Медиа, 2011. 640 с. [Kovalchuk L.V., Gankovskaya L.V., Meshkova R.Ya. Clinical immunology and allergology with the basics of general immunology]. Moscow: GEOTAR-Media, 2011. 640 p.

3. Научно-организационный комитет проекта ЭССЕ-РФ. Эпидемиология сердечно-сосудистых заболеваний в различных регионах России (ЭССЕ-РФ). Обоснование и дизайн исследования // Профилактическая медицина, 2013. Т. 16, № 6. С. 25-34. [Research organizing committee of the ESSE-RF project. Epidemiology of cardiovascular diseases in different regions of Russia (ESSE-RF). The rationale for and design of the study. Profilakticheskaya meditsina = Preventive Medicine, Vol. 16, no. 6, pp. 25-34. (In Russ.)]

4. Anders H.J., Baumann M., Tripepi G., Mallamaci F. Immunity in arterial hypertension: Associations or causalities? Nephrol. Dial. Transplant., 2015, Vol. 30, no. 12, pp. 1959-1964.

5. Barthelmes J., Nägele M.P., Ludovici V., Ruschitzka F., Sudano I., Flammer A.J. Endothelial dysfunction in cardiovascular disease and Flammer syndrome-similarities and differences. EPMA J., 2017, Vol. 8, no. 2, pp. 99-109.

6. Bernardo B.C., Weeks K.L., Patterson N.L., McMullen J.R. HSP70: therapeutic potential in acute and chronic cardiac disease settings. Future Med. Chem., 2016, Vol. 8, no. 18, pp. 2177-2183.

7. Bielecka-Dabrowa A., Barylski M., Mikhailidis D.P., Rysz J., Banach M. HSP 70 and atherosclerosis – protector or activator? Expert Opin. Ther. Targets, 2009, Vol. 13, no. 3, pp. 307-317.

8. Bomfim G.F., dos Santos R.A., Oliveira M.A., Giachini F.R., Akamine E.H., Tostes R.C., Fortes Z.B., Webb R.C., Carvalho M.H.C. Toll-like receptor 4 contributes to blood pressure regulation and vascular contraction in spontaneously hypertensive rats. Clin. Sci. (Lond)., 2012, Vol. 122, no. 11, pp. 535-543.

9. Cai W.-F., Zhang X.-W., Yan H.-M., Ma Y.-G., Wang X.-X., Yan J., Xin B.-M., Lv X.-X., Wang Q.-Q., Wang Z.-Y., Yang H.-Z., Hu Z.-W. Intracellular or extracellular heat shock protein 70 differentially regulates cardiac remodelling in pressure overload mice. Cardiovasc. Res., 2010, Vol. 88, no. 1, pp. 140-149.

10. Chebotareva N., Bobkova I., Shilov E. Heat shock proteins and kidney disease: perspectives of HSP therapy. Cell Stress and Chaperones, 2017, Vol. 22, no. 3. pp. 319-343.

11. Frantz S., Ertl G., Bauersachs J. Mechanisms of disease: Toll-like receptors in cardiovascular disease. Nat. Clin. Pract. Cardiovasc. Med., 2007, Vol. 4, no. 8. pp. 444-454.

12. Goulopoulou S., McCarthy C.G., Webb R.C. Toll-like receptors in the vascular system: Sensing the dangers within. Pharmacol. Rev., 2015, Vol. 68, no. 1, pp. 142-167.

13. Gruden G., Bruno G., Chaturvedi N., Burt D., Pinach S., Schalkwijk C., Stehouwer C.D., Witte D.R., Fuller J.H., Cavallo-Perin P. ANTI-HSP60 and ANTI-HSP70 antibody levels and micro/ macrovascular complications in type 1 diabetes: The EURODIAB Study. J. Intern. Med., 2009, Vol. 266, no. 6, pp. 527-536.

14. Herz I., Rosso R., Roth A., Keren G., George J. Serum levels of anti heat shock protein 70 antibodies in patients with stable and unstable angina pectoris. Acute Card. Care, 2006, Vol. 8, no. 1, pp. 46-50.

15. Hromadnikova I., Dvorakova L., Kotlabova K., Kestlerova A., Hympanova L., Novotna V., Doucha J., Krofta L. Circulating heat shock protein mRNA profile in gestational hypertension, pre-eclampsia & foetal growth restriction. Indian J. Med. Res., 2016, Vol. 144, no. 2, p. 229.

16. Kim Y.E., Hipp M.S., Bracher A., Hayer-Hartl M., Ulrich Hartl F. Molecular chaperone functions in protein folding and proteostasis. Annu. Rev. Biochem., 2013, Vol. 82, no. 1, pp. 323-355.

17. Li Y., Yu S., Gu G., Chen G., Zheng Y., Jiao J., Zhou W., Wu H., Zhang Z., Zhang H., He L., Yang Q., Xu X. Polymorphisms of heat shock protein 70 genes (HSPA1A, HSPA1B and HSPA1L) and susceptibility of noiseinduced hearing loss in a Chinese population: A case-control study. PLoS ONE, 2017, Vol. 12, no. 2, pp. 1-12.

18. Mardan-Nik M., Pasdar A., Jamialahmadi K., Avan A., Mohebati M., Esmaily H., Biabangard-Zak A., Afzal Javan F., Rivandi M., Ferns G.A., Ghayour-Mobarhan M. Association of heat shock protein70-2 (HSP70-2) gene polymorphism with obesity. Ann. Hum. Biol., 2016, Vol. 43, no. 6, pp. 542-546.

19. Mian M.O.R., Paradis P., Schiffrin E.L. Innate immunity in hypertension. Curr. Hypertens. Rep., 2014, Vol. 16, no. 2, p. 413.

20. Park K.-H., Park W.J. Endothelial dysfunction: Clinical implications in cardiovascular disease and therapeutic approaches. J. Korean Med. Sci., 2015, Vol. 30, no. 9, p. 1213.

21. Pockley A.G., de Faire U., Kiessling R., Lemne C., Thulin T., Frostegård J. Circulating heat shock protein and heat shock protein antibody levels in established hypertension. J. Hypertens., 2002, Vol. 20, no. 9, pp. 1815-1820.

22. Pockley A.G., Georgiades A., Thulin T., de Faire U., Frostegård J. Serum heat shock protein 70 levels predict the development of atherosclerosis in subjects with established hypertension. Hypertension, 2003, Vol. 42, no. 3, pp. 235-238.

23. Poon P.Y.K., Szeto C.C., Kwan B.C.H., Chow K.M., Li P.K.T. Relationship between HSP70-2 A+1267G polymorphism and cardiovascular events of chinese peritoneal dialysis patients. Nephron. Clin. Pract., 2014, Vol. 128, no. 1-2, pp. 153-158.

24. Pryshchep O., Ma-Krupa W., Younge B.R., Goronzy J.J., Weyand C.M. Vessel-specific toll-like receptor profiles in human medium and large arteries. Circulation, 2008, Vol. 118, no. 12, pp. 1276-1284.

25. Schlesinger M.J. Heat shock proteins. J. Biol. Chem., 1990, Vol. 265, no. 21, pp. 12111-12114.

26. Sharma S., Garg I., Ashraf M.Z. TLR signalling and association of TLR polymorphism with cardiovascular diseases. Vascul. Pharmacol., 2016, Vol. 87, pp. 30-37.

27. Srivastava K., Narang R., Bhatia J., Saluja D. Expression of heat shock protein 70 gene and its correlation with inflammatory markers in essential hypertension. PLoS ONE, 2016, Vol. 11, no. 3, pp. 1-15.

28. Teague H.L., Ahlman M.A., Alavi A., Wagner D.D., Lichtman A.H., Nahrendorf M., Swirski F.K., Nestle F., Gelfand J.M., Kaplan M.J., Grinspoon S., Ridker P.M., Newby D.E., Tawakol A., Fayad Z.A., Mehta N.N. Unraveling vascular inflammation: from immunology to imaging. J. Am. Coll. Cardiol., 2017, Vol. 70, no. 11. pp. 1403-1412.

29. Vogt S., Portig I., Kusch B., Pankuweit S., Sirat A.S., Troitzsch D., Maisch B., Moosdorf R. Detection of antihsp70 immunoglobulin G antibodies indicates better outcome in coronary artery bypass grafting patients suffering from severe preoperative angina. Ann. Thorac. Surg, 2004, Vol. 78, no. 3, pp. 883-889.

30. Wallin R.P.A., Lundqvist A., Moré S.H., von Bonin A., Kiessling R., Ljunggren H.G. Heat-shock proteins as activators of the innate immune system. Trends Immunol., 2002, Vol. 23, no. 3. pp. 130-135.

31. Wenzel U., Turner J.E., Krebs C., Kurts C., Harrison D.G., Ehmke H. Immune mechanisms in arterial hypertension. J. Am. Soc. Nephrol., 2016, Vol. 27, no. 3, pp. 677-686.

32. Xiao L., Liu Y., Wang N. New paradigms in inflammatory signaling in vascular endothelial cells. AJP Hear. Circ. Physiol., 2014, Vol. 306, no. 3, pp. H317-H325.

33. Zhang X., Tanguay R.M., He M., Deng Q., Miao X., Zhou L., Wu T. Variants of HSPA1A in combination with plasma Hsp70 and anti-Hsp70 antibody levels associated with higher risk of acute coronary syndrome. Cardiology, 2011, Vol. 119, no. 1, pp. 57-64.